Paclikaas NAB is a nanoparticle albumin-bound formulation of Paclitaxel, developed for enhanced delivery and reduced toxicity. It is indicated for the treatment of multiple cancers and offers an advanced, solvent-free alternative to conventional Paclitaxel.

Strength Available:

• Paclikaas NAB 100mg

Therapeutic Indications:

• Metastatic Breast Cancer

• Non-Small Cell Lung Cancer (NSCLC)

• Pancreatic Cancer (in combination therapy)

Mechanism of Action:
Paclitaxel stabilizes microtubules, preventing cell division and leading to apoptosis. The albumin-bound nanoparticle technology improves drug solubility and enhances transport across endothelial cells into tumors, increasing efficacy and reducing hypersensitivity reactions.

Key Features:

• Solvent-free formulation – no need for premedication with steroids or antihistamines

• Improved tolerability and bioavailability

• Faster infusion time

• GMP-certified manufacturing and stringent quality control

• Ready for intravenous infusion after dilution

Packaging:

• Single-dose sterile vial containing 100mg of Paclitaxel (albumin-bound)

Storage:
Store below 25°C. Do not freeze. Protect from light.

Note: To be administered under the supervision of a qualified oncologist or healthcare professional. Follow prescribed infusion protocols.